RainDance Technologies Continues Aggressive Expansion Across European Region

Mark Dronsfield appointed Director of Sales, Europe

LEXINGTON, Mass.--(BUSINESS WIRE)-- RainDance Technologies, Inc., a private company pioneering microdroplet-based technologies for single molecule and single cell analysis, today announced the latest addition to its worldwide commercial leadership team with the appointment of Mark Dronsfield, Ph.D., as Director of Sales for Europe. Dr. Dronsfield joins a growing commercial team of industry veterans that includes Richard H. Lussier, Vice President of Worldwide Sales and Ingrid Choupin, Managing Director of European Sales and Marketing.

“We are rapidly building a world-class sales and marketing organization dedicated to helping scientists around the world solve specific biological problems using our innovative microdroplet-based technology,” said Roopom Banerjee, President and CEO of RainDance Technologies. “Mark brings an unparalleled track-record of success in identifying, cultivating and closing sales opportunities for next-generation sequencing and PCR technology at the leading research institutions across Europe.”

As Director of Sales for Europe, Dr. Dronsfield will be responsible for advancing RainDance’s customer relationships and growth into the research and clinical markets. He brings 15 years of industry experience in life science sales and commercial operations and joins RainDance from Cell Biosciences where he was European Sales Director. Prior experience includes sales and marketing leadership positions at Solexa (now part of Illumina, Inc.), Affymetrix, and 10 years at Applied Biosystems (now part of Life Technologies, Inc.) where he was responsible for key European accounts including The Wellcome Trust Sanger Institute. He holds a BSc with honors in Biomedical Science from the Sheffield Hallam University and a Ph.D. in Genetics from the University of Birmingham.

“I have worked with Mark over the past five years and am continually impressed with his depth of knowledge and successful relationships with leaders on the cutting-edge of translational research in the European genetic analysis market,” said Lussier. “Mark will significantly strengthen our core on-the-ground sales operations, and I look forward to working with him as he helps build our presence in this important market.”

Adoption of RainDance’s innovative microdroplet-based technology is building momentum in Europe among organizations focused on a number of medically important application areas, including disease research and genetic screening in cancer, immunology, cardiology and childhood diseases. Earlier this year, the Max Plank Institute published data in The HUGO Journal on its use of the RainDance platform to screen patients with X-linked mental retardation (Hugo J. 2010 March 25). The company has also developed strategic partnerships with leading European service laboratories including Germany’s ATLAS Biolabs GmbH.

For more information, please visit www.raindancetech.com.

About RainDance Technologies

RainDance Technologies provides novel microdroplet-based solutions that accelerate breakthroughs in disease research, human healthcare and industrial markets. RainDance’s proprietary technology platform delivers exquisite sensitivity and data quality that inspires scientists, researchers and clinicians to rethink the way they design experiments, approach discovery, or conduct clinical care. The core RainStorm™ technology empowers customers to conduct de novo science in an ultra high throughput, simple, flexible, and low cost manner. The company provides resolution of molecular, biological and physiological events from large population samples to unprecedented single cell analysis, all inside a contained droplet microenvironment that enables quantification, single molecule sensitivity, and preserves sample integrity with no bias or contamination. RainDance’s commercial products include instruments and high-value consumables and reagents for targeted resequencing validation and sequence enrichment for next-generation sequencing, ultra-deep sequencing, and methylation analysis. RainDance sells directly in the U.S. and in Europe, and is building distribution networks in Europe and Asia-Pacific. RainDance Technologies, with headquarters in Lexington, MA and a European sales office in the United Kingdom, has approximately 75 employees worldwide.

RainStorm is a trademark of RainDance Technologies, Inc.


For RainDance Technologies
Colin Sanford, 203-340-2441
[email protected]

KEYWORDS:   United States  Europe  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Medical Devices  Other Science  Science